Barrier Therapeutics today announced favorable results for Rambazole in a European study in moderate to severe psoriasis:
Based on Investigators Global Assessment (IGA), 49% of patients receiving 2.0 mg per day of Rambazole were scored “cleared or almost cleared” at week 20 as compared to 20% for patients receiving placebo.
This was a Phase Two study of this experimenta drug, which is administered orally. The company says they are looking for partners to move the drug’s testing forward and will also seek to conduct future studies in the United States.
You can read more about the psoriasis drug and treatment pipeline here.
Category: Uncategorized
